Company intelligence / Profile preview
Entrada Therapeutics
Boston, Massachusetts, United Statesentradatx.com ↗
- Ownership
- Public · TRDA
- Employees
- ~183
- Development stage
- Phase 1
01
Overview
Entrada's lead candidate ENTR-601-44 for DMD had an FDA clinical hold lifted in February 2025 after being placed on hold in December 2022. The company has received authorization in the UK to initiate a Phase 1 clinical trial for ENTR-601-44 in August 2023, with the first participant expected to be dosed in September 2023. Data from this trial is anticipated in the second half of 2024. The company plans to start a Phase 1b trial in the first half of 2026.
- Therapeutic areas
- Metabolic DisordersOphthalmologyImmunologyRare DiseasesNeurology
- Modalities
- OligonucleotidesAntibodiesEnzymesPeptidesPhosphorodiamidate morpholino oligomers (PMOs)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Vertex Pharmaceuticals IncorporatedPierrepont Therapeutics, Inc.
04
Financials
- Market cap
- $276M
- Total revenue
- $898K
- Enterprise value
- $101.6M
Beyond the preview
Go deeper on Entrada Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Entrada Therapeutics.